Previous 10 | Next 10 |
NEWTON, Mass., May 23, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced tha...
The following slide deck was published by Acer Therapeutics Inc. in conjunction with this Read more ...
Acer Therapeutics (NASDAQ: ACER ): Q1 GAAP EPS of -$0.79 beats by $0.08 . Cash and equivalents of $31.8M. Press Release More news on: Acer Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, ,
NEWTON, Mass., May 14, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported fina...
NEWTON, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced tha...
Data by YCharts Acer Therapeutics Inc. (NASDAQ: ACER ) ("Acer" or the "Company") is a pharmaceutical company headquartered in Newton, Massachusetts focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significa...
Acer Therapeutics ( ACER ) - The company announced publication of long-term data from a cohort of COL3A1-positive Vascular Ehlers-Danlos Syndrome (vEDS) patients in the Journal of the American College of Cardiology. The trial describes outcomes for 144 COL3A1-positive vEDS patients cli...
NEWTON, Mass., April 16, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with critical unmet medical needs, today announced the ...
Sector Technicals Last week, the XBI (SPDR Biotech ETF) and IBB (iShares Nasdaq Biotechnology ETF) fell 4.16% and 3.38%, respectively. When markets have a tough week, take advantage of this opportunity to scan for stocks that are swimming upstream against the tide. Data by YCharts ...
Gainers: China Bat Group (NASDAQ: GLG ) +66% . Papa Murphy's Holdings (NASDAQ: FRSH ) +31% . Phunware (NASDAQ: PHUN ) +22% . Evofem Biosciences (NASDAQ: EVFM ) +18% . American Renal Associates Holdings (NYSE: ARA ) +15% . Acer Therapeutics (NASDAQ: ACER ) +14% . ZK Internation...
News, Short Squeeze, Breakout and More Instantly...
Acer Therapeutics Inc. Company Name:
ACER Stock Symbol:
NASDAQ Market:
Acer Therapeutics Inc. Website:
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Acer Therapeutics Inc. (ACER) is expected to report $-0.13 for Q3 2023